This great value stock is a better bet than Sirius Minerals plc

Royston Wild looks at a stock with more investment appeal than Sirius Minerals plc (LON: SXX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Whil FTSE 250 mining giant Sirius Minerals (LSE: SXX) could deliver blockbuster returns to patient investors, I am far more compelled by the investment outlook of Indivior (LSE: INDV), whose products tackle opioid addiction.

Its share price detonated to fresh record peaks above 400p last week, investor appetite still bubbling after significant regulatory news from across the Pond late last month. The US Food and Drug Administration is to fast-track Indivior’s new drug application for its revolutionary RBP-6000 formula, the world’s first once-monthly injectable buprenorphine treatment. The approval of this drug could unlock billions of dollars in revenues.

This is not the only positive news to come out of Indivior in recent weeks, the pharma ace having also hiked its profits guidance for the year in recent sessions.

Thanks to robust market conditions Stateside, still-solid demand for its Suboxone film product, and lower legal and R&D expenses, the company saw net income between January and June detonate 43%, to $153m. Net revenues rose 4% to $553m.

Indivior now expects net income to range between $265m and $285m in 2017, a significant uplift from its prior guidance of $200m to $220m.

The City expects the medicines marvel to record a 9% earnings advance in 2017, leaving it dealing on a forward P/E ratio of 16.6 times. I reckon this is solid value given the vast long-term sales potential of its heroin battler and consequent room for more meaty earnings upgrades further down the line.

Too much risk?

Share pickers may have to wait some time for a possible revenues explosion at Sirius Minerals however, its polyhalite asset on the North Yorkshire Moors not scheduled to produce maiden material until 2021.

It chalked up an operating loss of £14.1min H1, which widened from the £4.7m loss a year earlier. The digger attributed this to a “general increase in group activity following commencement of development.” It ploughed £121m into the project during the six months, of which £48.3m was capital expenditure.

Chief executive Chris Fraser remained upbeat despite the bottom-line slide, and said “the half year has been marked by excellent progress on the development of Woodsmith Mine and associated infrastructure.” The construction process remains on schedule and within budget, Sirius added.

The mining giant deserves applause for the huge strides it has made so far in executing its action plan. It is slowly but steadily putting the necessary production infrastructure in place; has raised boatloads of capital to get the plan off the ground; and its rapidly-expanding sales team has already booked agreements for around 3.6mt of material per year.

But the road to Sirius pulling the first fertiliser out of the ground remains a long and hazardous one. Any construction delays could eat up oodles of cash and result in the loss of massive amounts of revenue, putting extra strain on the company’s balance sheet. There is no guarantee that demand for its POLY4 product will turn out to be as strong as hoped for. And a lot more capital is needed for the development programme to remain on track.

Should everything continue to progress as planned, in five years time I could rue the decision not to invest in Sirius. But given the huge degree of risk thepolyhalite play still commands, I believe sitting on the sidelines is the right course of action for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »